natgillin/translations-raw huggingface dataset:
In women receiving etravirine 200 mg b.i.d., higher mean values for Cmax, AUC12h and Cmin were observed during pregnancy compared to postpartum.
Kod žena koje su uzimale etravirin 200 mg dva puta na dan, zabilježene su više srednje vrijednosti Cmax, AUC12h i Cmin tijekom trudnoće u usporedbi s postpartalnim razdobljem.
In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year.
Približno 2 žene na njih 10 000 koje ne koriste KHK-e i nisu trudne razvit će VTE u razdoblju od godinu dana.
In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year.
Približno 2 žene na njih 10 000 koje ne koriste KOK-e i nisu trudne razvit će VTE u razdoblju od godinu dana.
In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.
Kod žena u postmenopauzi Prolia smanjuje rizik od fraktura kralježnice i drugih dijelova tijela, uključujući kuk.
In women who have been through the menopause, levels of the sex hormone oestrogen fall.
Koncentracije spolnog hormona estrogena smanjuju se u žena koje su prošle kroz menopauzu.
In women whose endogenous gonadotrophin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.
U žena sa supresijom lučenja endogenog gonadotropina, pokazalo se da folitropin alfa ipak učinkovito stimulira razvoj folikula i steroidogenezu, unatoč nemjerljivim razinama LH.
In women whose endogenous gonadotropin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.
U žena sa supresijom lučenja endogenog gonadotropina pokazalo se da folitropin alfa ipak učinkovito stimulira razvoj folikula i steroidogenezu, unatoč nemjerljivim razinama LH-a.
In women with an intact uterus, the risk of endometrial hyperplasia and carcinoma is increased when oestrogens are administered alone for prolonged periods.
U žena s očuvanom maternicom, dugotrajno liječenje samim estrogenima povećava rizik od hiperplazije endometrija i karcinoma.
In women with anovulation, the objective of therapy with follitropin alfa is to develop a single mature Graafian follicle from which the ovum will be liberated after the administration of hCG.
U žena s anovulacijom, cilj terapije folitropinom alfa je razviti jedan zreli Graafov folikul iz kojeg će se nakon davanja hCG osloboditi jajna stanica.
In women with baseline femoral neck BMD  -2.5, Prolia reduced the risk of non-vertebral fracture (35% relative risk reduction, 4.1% absolute risk reduction, p < 0.001, exploratory analysis).
Prolia je smanjila rizik od nevertebralnih fraktura u žena s inicijalnim BMD vrata femura  -2,5; (35% smanjenje relativnog rizika: 4,1% smanjenje apsolutnog rizika; p < 0,001; eksplorativna analiza).
In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.
U žena s nasljednim angioedemom, egzogeni estrogen može izazvati ili pogoršati simptome angioedema.
In women with hereditary angioedema, exogenous oestrogens may induce or exacerbate symptoms of angioedema.
U žena s nasljednim angioedemom, egzogeni estrogen može izazvati ili pogoršati simptome angioedema.
In women with no personal history of VTE but with a first-degree relative with a history of thrombosis at young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening).
Ženama koje u osobnoj anamnezi nemaju VTE, ali imaju srodnicu prvog stupnja koja je imala trombozu u mlađoj dobi, mogu se ponuditi pretrage pomno uzimajući u obzir njihova ograničenja (pretragom se može otkriti samo dio trombofilijskih poremećaja).
In women with osteoporosis who had been through the menopause, Prolia was more effective than placebo at reducing fractures.
U žena s osteoporozom u postmenopauzi lijek Prolia bio je djelotvorniji od placeba u smanjenju broja fraktura.
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thrombo-embolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events.
U žena s nedavnom ili postojećom tromboembolijskom bolešću ili u žena s općepoznatim čimbenicima rizika za tromboembolijske događaje, kao što su tromboembolijski događaji u osobnoj ili obiteljskoj anamnezi, liječenje gonadotropinima može dodatno povećati rizik od pogoršanja ili nastanka takvih događaja.
In women, safe and effective use of follitropin alfa calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis.
U žena sigurna i učinkovita primjena folitropina alfa iziskuje redovito praćenje odgovora jajnika ultrazvukom, samostalno ili čak i bolje u kombinaciji s redovitim mjerenjem razine estradiola u serumu.
In women, safe and effective use of Pergoveris calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis.
Kod žena, za sigurno i učinkovito korištenje lijeka Pergoveris, potrebno je redovito praćenje odgovora jajnika na terapiju ultrazvučno ili bolje kombinacijom ultrazvuka i praćenja razina estradiola userumu.
In young adult cattle and pig studies, gamithromycin was administered by injection at 6, 18, and 30 mg/kg (1, 3, and 5 times the recommended dose) and repeated three times at 0, 5 and 10 days (three times the recommended duration of use).
U ispitivanjima na mladim odraslim govedima i svinjama, injiciran je gamitromicin subkutano po 6, 18, i 30 mg/kg (1, 3, i 5-kratno preporučena doza), ponovljen tri puta u 0, 5 i 10 dana (trostruko preporučeno trajanje primjene).
In young pigs weighing approximately 10 kg given three or five times the therapeutic dose transient signs attributed to injection site discomfort were observed and included excessive vocalisation and restlessness.
Kod odojaka od približno 10 kg, koji su dobili trostruku ili peterostruku terapijsku dozu uočeni su prolazni znakovi koji se pripisuju boli na mjestu injiciranja i uključuju pretjerano glasanje i nemir.
In young pigs weighing approximately 10 kg given three or five times the therapeutic dose transient signs attributed to injection site discomfort were observed and included excessive vocalisation and restlessness.
Kod odojaka teških približno 10 kg koji su dobili trostruku ili peterostruku terapijsku dozu uočeni su prolazni znakovi koji se pripisuju boli na mjestu injiciranja i uključuju pretjerano glasanje i nemir.
In young subjects, Dynastat 40 mg twice daily had no clinically significant effect on acetylsalicylic acid - mediated inhibition of platelet function (see section 4.5).
U mladih ispitanika, Dynastat u dozi od 40 mg dvaput dnevno nije imao klinički značajnog učinka na inhibiciju funkcije trombocita posredovanu acetilsalicilnom kiselinom (vidjeti dio 4.5).
In younger children from two months of age, and in children weighing less than 33 kilograms, the recommended dose depends on the weight of the patient.
U djece mlađe od dva mjeseca i u djece čija je tjelesna težina manja od 33 kilograma preporučena doza ovisi o težini bolesnika.
In younger children, two injections are given (at an interval of at least two months), except in infants aged between two and five months who receive three injections (at intervals of at least one month).
Mlađoj djeci daju se dvije injekcije (u intervalu od najmanje dva mjeseca), osim dojenčadi stare između dva i pet mjeseci kojoj se daju tri injekcije (u intervalima od najmanje mjesec dana).
In younger patients, the most common side effects (seen in between 1 and 10 in 100 patients) are upper respiratory tract infections, ear infection, blood in the urine and fever.
Kod mlađih bolesnika najčešće nuspojave (uočene kod 1 do 10 na 100 bolesnika) su infekcije gornjih dišnih puteva, upale uha, krv u mokraći te vrućica.
in your brain in your abdomen, lungs or in the membrane surrounding the heart
u mozgu u trbuhu, plućima ili opni koja prekriva srce
in your brain or in your spinal column
u mozgu ili kralježnici
in your eyes
u oči
in your eyes
u očima
in your eyes and bruise of the eyes
u očima i modrice oko očiju
In your first treatment cycle, you may be treated every day up to 50 days at most or until your doctor determines that your disease is better.
U Vašem prvom ciklusu liječenja možda ćete dobivati TRISENOX svaki dan do 50 dana najviše ili dok liječnik ne utvrdi da Vam je bolje.
in your mouth or blood in your spit when coughing
u ustima ili krv u ispljuvku kod iskašljavanja
in your stomach, bowel or dark/black blood in the stools
u želucu, crijevima ili tamna/crna krv u stolici
In, study MDS-003, in which 148 patients received lenalidomide at a dose of 10 mg, the primary efficacy analysis consisted of an evaluation of the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk myelodysplastic syndromes.
U ispitivanju MDS-003 u kojemu je 148 bolesnika primalo lenalidomid u dozi od 10 mg, analizu primarne djelotvornosti činila je procjena djelotvornosti terapija lenalidomidom u smislu postizanja hematopoetskog poboljšanja u ispitanika s mijelodisplastičnim sindromima niskog ili srednjeg - 1 rizika.
In-feed use
Primjena u hrani.
In-feed use.
Umiješano u hranu za životinje.
In-ovo equipment should be calibrated to ensure that a 0.05 ml dose is applied to each egg.
Oprema za in-ovo primjenu mora biti kalibrirana kako bi se osiguralo da je na svako jaje primijenjena doza od 0,05 ml.
In-use cartridges
Ulošci u uporabi
In-use cartridges:
Ulošci u uporabi
In-use OptiSet, a dose of 2 units has to be selected by turning the dosage selector forward till the dose arrow points to 2.
Kod OptiSet brizgalice u uporabi moraju se odabrati 2 jedinice okretanjem izbornika doze prema naprijed dok strelica za dozu ne pokaže 2.
In-use OptiSet, a dose of 2 units has to be selected by turning the dosage selector forward till the dose arrow points to 2.
Kod OptiSet brizgalice u uporabi, moraju se odabrati 2 jedinice okretanjem izbornika doze prema naprijed dok strelica za dozu ne pokaže 2.
In-use OptiSet: select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2.
OptiSet u uporabi: odaberite dozu od 2 jedinice okretanjem izbornika doze prema naprijed dok strelica za dozu ne pokaže 2.
In-use Pen
Brizgalica u uporabi
In-use shelf life
Rok valjanosti nakon otvaranja
In-use shelf life after 1st opening:
Rok valjanosti nakon prvog otvaranja:
In-use shelf life after mixing: 2 hours.
Nakon miješanja rok valjanosti: 2 sata.
In-use shelf life: 2 months
Rok valjanosti nakon otvaranja: 2 mjeseca.
In-use shelf life: 30 days.
Rok valjanosti od otvaranja: 30 dana.
In-use shelf-life after opening the tray: 6 weeks
Rok valjanosti nakon otvaranja podloška: 6 tjedana
In-use stability after first opening and/or dilution: from a microbiological point of view, after dilution, the reconstituted medicinal product should be used immediately.
Stabilnost lijeka u primjeni nakon prvog otvaranja i/ili razrjeđivanja: s mikrobiološkog stajališta, nakon razrjeđivanja rekonstituirani lijek mora se upotrijebiti odmah.
In-use stability demonstrated for 3 hours at 2- 8 °C.
Dokazana stabilnost otopine u primjeni je 3 sata na temperaturi od 2 do 8 °C.
In-use stability demonstrated for 3 hours at 2- 8 °C.
Dokazana stabilnost otopine u primjeni je 3 sata na temperaturi od 2 do 8°C.
In-use stability demonstrated for 3 hours at 2- 8°C.
Dokazana stabilnost otopine u primjeni je 3 sata na temperaturi od 2 do 8 °C.
In-use stability demonstrated for 3 hours at 2-8 °C.
Dokazana stabilnost otopine u primjeni je 3 sata na 2-8 °C.
In-use stability has been demonstrated for 2 days at 2 °C – 8 °C.
Stabilnost lijeka u primjeni dokazana je za trajanje od 2 dana na temperaturi 2 °C - 8 °C.
In-use stability shelf-life: Unused Siklos 1000 mg broken tablets must be replaced in the bottle and must be used within three months”
Rok valjanosti i stabilnost lijeka u primjeni: Neupotrijebljene izlomljene Siklos tablete od 1000 mg moraju se spremiti natrag u bočicu i obvezno upotrijebiti u roku od tri mjeseca.
In-use stability: Chemical and physical in-use stability after dilution has been demonstrated for 24 hours at 2 – 8 °C and 25 °C.
Stabilnost u primjeni: dokazana kemijska i fizikalna stabilnost nakon razrjeđenja iznosi 24 sata na temperaturi od 2 – 8 °C i 25 °C.
In-use storage conditions
Uvjeti čuvanja u primjeni
In-use storage times and conditions should not exceed 2 hours at room temperature (15 °C – 30 °C).
Vrijeme i uvjeti čuvanja ne smiju prelaziti 2 sata pri sobnoj temperaturi (15 °C-30 °C).
In-use tube: 7 days.
Tuba u primjeni: 7 dana.
In-vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the six major CYP isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
In vitro studije na humanim jetrenim mikrosomima pokazuju da ertapenem ne inhibira metabolizam posredovan bilo kojim od šest glavnih CYP izoformi: 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4.
In-vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
Istraživanja in vitro ukazuju da ertapenem ne inhibira transport digoksina i vinblastina posredovan P-glikoproteinom, kao i da ertapenem nije supstrat za transport posredovan P-glikoproteinom.
In-vitro studies indicate that the effect of ertapenem on the plasma protein binding of highly protein bound medicinal products (warfarin, ethinyl estradiol, and norethindrone) was small.
In vitro studije ukazuju da ertapenem ima malen učinak na vezivanje za proteine plazme onih lijekova koji se snažno vežu na te proteine (varfarin, etinilestradiol i noretindron).
In-vitro studies showed that delamanid and metabolites did not have any effect on the transporters MDR1(p- gp), BCRP, OATP1, OATP3, OCT1, OCT2, OATP1B1, OATP1B3 and BSEP, at concentrations of approximately 5 to 20 fold greater than the Cmax at steady state.
In-vitro ispitivanja su pokazala da delamanid i metaboliti nisu imali nikakvog učinka na transportere MDR1(p-gp), BCRP, OATP1, OATP3, OCT1, OCT2, OATP1B1, OATP1B3 i BSEP, u koncentracijama približno 5 do 20 puta većim od Cmax u stanju dinamičke ravnoteže.
In-vivo and ex-vivo animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.
In-vivo i ex-vivo ispitivanja na životinjama pokazala su antitrombotsku djelotvornost i antikoagulacijsku aktivnost dabigatrana nakon intravenske primjene te dabigatraneteksilata nakon oralne primjene u raznim modelima tromboze.
In-vivo and ex-vivo animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.
In-vivo i ex-vivo ispitivanja na životinjama pokazala su antitrombotsku djelotvornost i antikoagulacijsku aktivnost dabigatrana nakon intravenske primjene te dabigatraneteksilata nakon peroralne primjene u raznim modelima tromboze.
Inability for your eye to sense pain (anaesthesia of the cornea or conjunctiva or hypoaesthia)
gubitak osjeta za bol u oku (anestezija ili hipoestezija rožnice ili spojnice)
Inability of the body to respond normally to severe stress such as accidents, surgery or illness due to insufficient function of the adrenal glands, severe unusual headache with visual disturbances linked to the withdrawal of treatment, irregularity of menstrual cycles in women;
Nemogućnost tijela da normalno odgovori na teški oblik stresa poput nesreće, kirurškog zahvata ili bolesti zbog nedovoljne funkcije nadbubrežne žlijezde, ozbiljne neuobičajene glavobolje s poremećajima vida povezanima s ustezanjem od liječenja, nepravilnosti menstrualnog ciklusa u žena;
Inability of the heart to maintain adequate blood circulation.
nesposobnost srca da održi odgovarajuću cirkulaciju krvi
Inability of the heart to pump enough blood round the body (heart failure);
Nemogućnost srca da pumpa dovoljnu količinu krvi u tijelu (zatajenje srca);
inability of the liver
labljenje jetrene funkcije
inability to achieve or maintain an erection
nemogućnost postizanja ili održavanja erekcije
Inability to completely empty the bladder (urinary retention)
Nemogućnost potpunog pražnjenja mokraćnog mjehura (retencija urina)
Inability to control your bowel movements.
nemogućnost kontrole stolice.
inability to control your bowels;
nemogućnost kontole crijeva;
inability to control your bowels;
nemogućnost kontrole crijeva;
Inability to develop or maintain an erection
nemogućnost postizanja ili održavanja erekcije
inability to develop or maintain an erection chills, flu-like illness
nesposobnost postizanja ili održavanja erekcije zimica, bolest nalik gripi
inability to either stand or walk in a normal manner
nemogućnost ili stajanja ili hodanja na normalan način
inability to fall asleep or stay asleep
nemogućnost da usnivanja ili prosnivanja
inability to fall asleep or stay asleep
nemogućnost usnivanja ili prosnivanja
inability to get or maintain an erection
nesposobnost postizanja ili održavanja erekcije
Inability to heal properly.
nemogućnost pravilnog zacjeljivanja.
inability to pass urine
nemogućnost mokrenja
inability to pass urine
nemogućnost mokrenja,
Inability to pass urine.
nemogućnost mokrenja
inability to pass water (urinate) fever
nemogućnost mokrenja vrućica
Inability to produce enough insulin or resistance to normal levels of insulin
nemogućnost stvaranja dovoljno inzulina ili rezistencija na normalne razine inzulina
inability to reach orgasm
nemogućnost postizanja orgazma
Inability to resist the impulse to perform an action that could be harmful, which may include:
Nemogućnost odupiranja impulsu (porivu) za obavljanje određene radnje koja može biti štetna, što može uključivati:
Inability to resist the impulse to perform an action that could be harmful, which may include:
Nemogućnost odupiranja impulsu za neki postupak koji može biti štetan, što može uključivati:
inability to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, binge eating, compulsive eating and compulsive shopping swelling of legs and feet
nesposobnost odupiranja porivima za obavljanje štetnih radnji, kao što su pretjerano kockanje, ponavljajuće besmislene radnje, prejedanje, kompulzivno uzimanje hrane i kompulzivno kupovanje oticanje nogu i stopala
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Nemogućnost odupiranja nagonu, porivu ili iskušenju za vršenje radnji koje bi mogle naškoditi Vama ili drugima, što može uključivati:
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Nemogućnost oduprijeti se impulsu, nagonu ili iskušenju za obavljanjem određenih aktivnosti koje bi mogle naškoditi Vama ili drugima, koje mogu uključivati:
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Nesposobnost odupiranja nagonu, porivu ili iskušenju za vršenje radnji koje bi mogle naškoditi Vama ili drugima, što može uključivati:
inability to sleep
nesanica
inability to sleep (insomnia)
nemogućnost spavanja (nesanica)
inability to sleep (insomnia)
nesanica (insomnija)
inability to sleep (insomnia); cough; dyspnoea (breathing difficulties).
nesanica (insomnija); kašalj; dispneja (otežano disanje).
inability to sleep headache
nemogućnost spavanja glavobolja
inability to sleep,
nemogućnost spavanja,
inability to sleep,
nesanica
Inability to sleep, depression, changed sense of taste
nesanica, depresija, promjena osjeta okusa
inability to sleep, hallucinations, confusion abnormal dreams (including nightmares), tiredness
nesanica, halucinacije, smetenost, poremećeni snovi (uključujući noćne more), umor
inability to sleep, hallucinations, confusion, abnormal dreams (including nightmares), tiredness
nesanica, halucinacije, smetenost, poremećeni snovi (uključujući noćne more), umor
Inability to speak or write or understand spoken or written language;
Nesposobnost govora ili pisanja ili razumijevanja govornog ili pisanog jezika;
Inability to stand or sit upright for at least 30 minutes.
Nemogućnost stajanja ili uspravnog sjedenja najmanje 30 minuta.
Inability to stand or sit upright for at least 60 minutes
Nemogućnost stajanja ili uspravnog sjedenja barem 60 minuta
inability to sweat normally
nemogućnost normalnog znojenja
inability to taste (ageusia)
gubitak osjeta okusa (ageuzija)
Inability to tolerate alcohol consumption
netoleracija na konzumaciju alkohola
Inability to urinate
nemogućnost mokrenja
Inability to walk due to imbalance Inflammation of pancreas or intestine Loss of memory
nemogućnost hodanja zbog nestabilnosti upala gušterače ili crijeva
Inactivated
BTV-1/ALG2006/01 E1
Inactivated Bluetongue Virus ......................................... strain specific pass level (log10 pixels) ** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktivirani virus bolesti plavog jezika ………………≥nivo specifičnog soja (log10 piksela)** (*) maksimum dva različita serotipa inaktiviranog virusa
Inactivated Bluetongue Virus Serotype 1................................................................. 1.9 log10 pixels* (*) Antigen content (VP2 protein) by immuno-assay
Inaktivirani Virus protiv bolesti plavog jezika Serotip1 ............................................ 1,9 log10piksela (*) Antigen sadržava (VP2 protein) imuno-testa
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 Aluminium hydroxide, saponin and thiomersal.
Inaktivirani virus bolesti plavog jezika, serotip 1, soj BTV-1/ALG2006/01 E1, Aluminijev hidroksid, saponin i tiomersal.
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02
Inaktivirani virus bolesti plavog jezika, serotip 1, soj BTV-1/ALG2006/01 E1 Inaktivirani virus bolesti plavog jezika, serotip 8, soj BTV- 8/BEL2006/02
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1
Inaktivirani virus bolesti plavog jezika, serotip 1, soj BTV-1/ALG2006/01 E1 RP* ≥ 1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktivirani virus bolesti plavog jezika, serotip 1, soj BTV-1/ALG2006/01 E1 RP* ≥ 1 Inaktivirani virus bolesti plavog jezika, serotip 8, soj BTV-8/BEL2006/02 RP* ≥ 1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktivirani virus bolesti plavog jezika, serotip 1, soj BTV-1/ALG2006/01 E1 RP*≥1 Inaktivirani virus bolesti plavog jezika, serotip 8, soj BTV-8/BEL2006/02 RP*≥1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1, Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktivirani virus bolesti plavog jezika, serotip 1, soj BTV-1/ALG2006/01 E1 RP*≥1 Inaktivirani virus bolesti plavog jezika, serotip 8, soj BTV-8/BEL2006/02 RP*≥1
Inactivated Bluetongue Virus............................................ strain specific pass level (log10 pixels)** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktivirani virus bolesti plavog jezika BTV………………………………≥nivo specifičnog soja( log10piksela)** (*) maksimum dva različita serotipa inaktiviranog virusa
Inactivated Bordetella bronchiseptica, strain 833CER: .............................................
Inaktivirani soj bakterije Bordetella bronchiseptica, 833CER: .................................